JP2024542844A - アルツハイマー病の処置に使用されるａｌｚ－８０１ - Google Patents

アルツハイマー病の処置に使用されるａｌｚ－８０１ Download PDF

Info

Publication number
JP2024542844A
JP2024542844A JP2024534268A JP2024534268A JP2024542844A JP 2024542844 A JP2024542844 A JP 2024542844A JP 2024534268 A JP2024534268 A JP 2024534268A JP 2024534268 A JP2024534268 A JP 2024534268A JP 2024542844 A JP2024542844 A JP 2024542844A
Authority
JP
Japan
Prior art keywords
alz
day
dose
subject
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024534268A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024542844A5 (enExample
Inventor
アブシャクラ，スーザン
フランズライチ，ニール・ウィリアム
ヘイ，ジョン
トラル，マーティン
Original Assignee
アルツェオン・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルツェオン・インコーポレーテッド filed Critical アルツェオン・インコーポレーテッド
Publication of JP2024542844A publication Critical patent/JP2024542844A/ja
Publication of JP2024542844A5 publication Critical patent/JP2024542844A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2024534268A 2021-12-09 2022-12-09 アルツハイマー病の処置に使用されるａｌｚ－８０１ Pending JP2024542844A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163287552P 2021-12-09 2021-12-09
US63/287,552 2021-12-09
PCT/US2022/052331 WO2023107658A1 (en) 2021-12-09 2022-12-09 Alz-801 for use in treating alzheimer's disease

Publications (2)

Publication Number Publication Date
JP2024542844A true JP2024542844A (ja) 2024-11-15
JP2024542844A5 JP2024542844A5 (enExample) 2025-12-11

Family

ID=85157530

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024534268A Pending JP2024542844A (ja) 2021-12-09 2022-12-09 アルツハイマー病の処置に使用されるａｌｚ－８０１

Country Status (10)

Country Link
US (1) US20250041248A1 (enExample)
EP (1) EP4444286A1 (enExample)
JP (1) JP2024542844A (enExample)
KR (1) KR20240116529A (enExample)
CN (1) CN118678950A (enExample)
AU (1) AU2022405026A1 (enExample)
CA (1) CA3240392A1 (enExample)
IL (1) IL313404A (enExample)
MX (1) MX2024007070A (enExample)
WO (1) WO2023107658A1 (enExample)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3347002T (pt) * 2015-09-10 2023-07-27 Alzheon Inc Tratamento de doença de alzheimer numa população particular de pacientes
DK3829563T3 (en) * 2018-08-01 2025-02-24 Alzheon Inc 3-sulfopropanoic acid for treating neurodegenerative disorders

Also Published As

Publication number Publication date
AU2022405026A1 (en) 2024-06-20
EP4444286A1 (en) 2024-10-16
IL313404A (en) 2024-08-01
CA3240392A1 (en) 2023-06-15
WO2023107658A1 (en) 2023-06-15
US20250041248A1 (en) 2025-02-06
KR20240116529A (ko) 2024-07-29
CN118678950A (zh) 2024-09-20
MX2024007070A (es) 2024-08-22

Similar Documents

Publication Publication Date Title
Muller et al. Depression and anxiety occurring during Rauwolfia therapy
JP5289765B2 (ja) 自閉症、強迫神経症、および衝動性の治療のためのメマンチン（ナメンダ）の使用
Siani et al. Controlled trial of long term oral potassium supplements in patients with mild hypertension.
Blaszak et al. The use of short-acting nifedipine in pediatric patients with hypertension
Sydenstricker et al. The effect of nicotinic acid in stupor, lethargy and various other psychiatric disorders
ES3062607T3 (en) Cannabinoid composition and application thereof in preparation of drug for treating neurodegenerative diseases such as parkinson's disease and alzheimer's disease
JP2026031955A (ja) 自閉症スペクトラム障害の症状を治療する方法
WO2022115576A2 (en) Treatment of raynaud's disease
EA029650B1 (ru) 4-гидрокси-2-метил-5-(пропан-2-илиден)циклогекс-3-энекарбальдегид в профилактике и лечении когнитивных, нейродегенеративных или нейронных заболеваний
US20150374691A1 (en) Methods and materials for treating orthostatic hypotension or postural tachycardia syndrome
US20250041248A1 (en) Alz-801 for use in treating alzheimer's disease
US20240408086A1 (en) Use of luvadaxistat for the treatment of cognitive impairment
SCOTT et al. The Jarisch-Herxheimer phenomenon in late syphilis: Probable fatal reactions to penicillin
Dreyer Pharmacology for nurses and other health workers
RU2844953C1 (ru) Способы лечения симптомов расстройства аутистического спектра
RU2763332C1 (ru) Способ коррекции когнитивных функций при монотерапии эпилепсии у детей
Friedlander Cortisone as an adjunct in the therapy of acute gout
TW200533341A (en) Therapeutic combination for treatment of alzheimer's disease
WO2025145241A1 (en) Treatment of gut-brain interaction disorders
WO2025018279A1 (ja) ヒト移植片対宿主病の治療薬およびその組合せ物
Howard The diagnosis and treatment of malignant hypertension
WO2025245322A1 (en) Oxytocin-based therapeutics to improve cognitive control in individuals with attention-deficit/hyperactivity disorder
CN117580576A (zh) Luvadaxistat用于治疗认知损害的用途
EA052181B1 (ru) Каннабиноидная композиция и ее применение для получения лекарственного средства для лечения нейродегенеративных заболеваний, таких как болезнь паркинсона и болезнь альцгеймера
JP2024542844A5 (enExample)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251203